News Channels

Show Cart

News Channels

21 Oct 2017	Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
21 Oct 2017	Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
21 Oct 2017	uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
21 Oct 2017	DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
20 Oct 2017	DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
20 Oct 2017	Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
20 Oct 2017	Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
19 Oct 2017	AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris
19 Oct 2017	Roivant Sciences Enters into Development Partnership with AstraZeneca
19 Oct 2017	OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
19 Oct 2017	Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results For Its Novel Antiepileptic Agent
19 Oct 2017	Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
19 Oct 2017	Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
19 Oct 2017	Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
19 Oct 2017	Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
19 Oct 2017	Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
19 Oct 2017	Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
19 Oct 2017	OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
19 Oct 2017	Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
19 Oct 2017	Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee